In the current retrospective analysis, we demonstrate the utility of an AI-based tool (AIM-NASH) for scoring NASH histology of liver biopsies from a Phase 2 trial of resmetirom (MGL-3196), a liver-targeted, oral, once-daily selective thyroid hormone receptor-β agonist in development for treatment of NASH with significant fibrosis.
Reference:
Harrison SA, et al. Lancet. 2019;394(10213):2012-2024. Harrison et al.
Reference:
Harrison SA, et al. Lancet. 2019;394(10213):2012-2024. Harrison et al.
